Eli Lilly is expanding its commitment to artificial intelligence-driven drug development, signing a deal with Hong Kong-based Insilico to develop and commercialize experimental drugs in preclinical development.
Healthcare Dive published a clinical update in Research Highlights on 30 Mar 2026.
The item focuses on Lilly’s AI commitment expands through deal with Insilico.
Review the original article for the full source wording and details.